The Leukemia & Lymphoma Society* and*Epizyme announced today that they have achieved a pre-clinical milestone in their partnership to develop Epizyme’s DOT1L-targeted histone methyltransferase inhibitor for Mixed Lineage Leukemia , a devastating acute leukemia that affects both pediatric and adult patients.
More...
More...